Protagonist Therapeutics, Inc.
PTGX
Kedudukan dalam Saham
#2247
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Harga Saham
$138.50
Modal Pasaran
$8.96B
Perubahan (1 hari)
3.02%
Perubahan (1 tahun)
80.53%
Negara
US
Perdagangan Protagonist Therapeutics, Inc. (PTGX)
Kategori
Healthcare
Pendapatan untuk Protagonist Therapeutics, Inc. (PTGX)
Pendapatan pada Jun 2026 TTM: $84.34M
Menurut laporan kewangan terkini Protagonist Therapeutics, Inc., pendapatan semasa syarikat ialah $84.34M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-78.96M, peningkatan berbanding pendapatan pada tahun 2022 yang berjumlah $-127.39M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Protagonist Therapeutics, Inc. dari 2014 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $84.34M | -69.82% |
| 2024 | $279.41M | -453.88% |
| 2023 | $-78.96M | -38.02% |
| 2022 | $-127.39M | 1.47% |
| 2021 | $-125.55M | 93.62% |
| 2020 | $-64.85M | -16.74% |
| 2019 | $-77.88M | 96.05% |
| 2018 | $-39.72M | 7.48% |
| 2017 | $-36.96M | -0.59% |
| 2016 | $-37.18M | 150.22% |
| 2015 | $-14.86M | 34.19% |
| 2014 | $-11.07M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | 6,154.48% |
US
|
|
| $-3.09B | -3,760.27% |
US
|
|
| $-4.02B | -4,862.02% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 2,212.90% |
NL
|
